

2021/5/10

Company: CYBERDYNE Inc.

Name of Yoshiyuki Sankai, Representative: President and CEO

Code: 7779 (Mothers Section of the Tokyo

Stock Exchange)

Contact: Shinji Uga, Director and CFO

(Tel. +81-29-869-9981)

## [News] HAL installed to the largest public hospital in Indonesia

CYBERDYNE Inc. [Tsukuba, Ibaraki, CEO: Yoshiyuki Sankai (the "Company")] exported HAL Lower Limb Type to Dr. Cipto Mangunkusumo National Central Public Hospital (In Indonesian: Rumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo. To be referred to as "RSCM"). The hospital is known to be one of the largest national public hospitals in Indonesia.

RSCM serves as a teaching hospital for the University of Indonesia, and it is said to be the nation's leading teaching hospital. The hospital is run by the Indonesian Ministry of Health, making the hospital well-resourced with advanced diagnostic and therapeutic medical technology. While there are five Class A national hospitals in Jakarta SAR, RSCM is one of the largest national hospitals in the country.



Photo of RSCM (cited from the website of RSCM)

The Company schedules to install two units of HAL Lower Limb Type to the rehabilitation department of the RSCM. The doctors involved in this project are certified operators of HAL. They are confident that Cybernics Technology

such as HAL can enhance the effectiveness of treatment and help in the rehabilitation and recovery of many patients.

In consideration of travel restrictions due to the spread of the COVID-19, the Company will install HAL and provide support remotely. The Company will continue to deploy Cybernics Treatment, an innovative medical technology originating from Japan in Indonesia, to create a society of health and longevity where all people can enjoy healthy and affluent lives.

<Link>

HAL Lower Limb Type obtained medical device approval for Indonesia ~Approved for a wide range of diseases in the 4th most populated nation~ <a href="https://www.cyberdyne.jp/wp-uploads/2020/04/200430">https://www.cyberdyne.jp/wp-uploads/2020/04/200430</a> PR ENG2.pdf